




RealRate

PHARMACEUTICAL 2018

Ocuphire Pharma Inc.
Rank 270 of 349



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2018

Ocuphire Pharma Inc.
Rank 270 of 349



The relative strengths and weaknesses of Ocuphire Pharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Ocuphire Pharma Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 123% points. The greatest weakness of Ocuphire Pharma Inc. is the variable Net Income, reducing the Economic Capital Ratio by 225% points.

The company's Economic Capital Ratio, given in the ranking table, is -423%, being 146% points below the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	28,136
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	0
Liabilities, Non-Current	0
Other Assets	31
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	11,519
Other Net Income	-7,940
Property and Equipment	121
Research and Development	10,715
Revenues	0
Selling, General and Administrative Expense	6,639

Output Variable	Value in 1000 USD
Assets	28,288
Liabilities	11,519
Expenses	17,355
Stockholders Equity	16,769
Net Income	-25,295
Comprehensive Net Income	-25,295
Economic Capital Ratio	-423%

